RESUMEN
This study was conducted to investigate the potential association of genetic polymorphisms of glutathione S-transferase M1/T1 (GSTM1, GSTT1), and N-acetyltransferase 2 (NAT2) genes and epidemiological parameters with the risk of HCC in the Algerian population.A case-control study including 132 confirmed HCC patients and 141 cancer-free controls was performed. Genotyping analysis was performed using conventional multiplex PCR and PCR-RFLP. Statistical analysis was performed using the Chi-square test. Logistic regression analysis was used to estimate odds ratios and 95% confidence intervals (95% CI).GSTM1 null and NAT2 slow acetylator genotypes confer an increased risk to HCC (OR = 1.88, 95% CI 1.16-3.05; OR = 2.30, 95% CI 1.26-4.18, respectively). This association was prevalent in smokers (OR = 2.00, 95% CI 1.05-3.8 and OR = 2.55, 95% CI 1.22-5.34, respectively). No significant association was observed for GSTT1 null genotype in the contribution to HCC risk (OR = 0.76, 95% CI 0.46-1.27).In conclusion, the GSTM1 and NAT2 gene polymorphisms are positively associated with the risk of HCC in older men and especially in smokers.
Asunto(s)
Arilamina N-Acetiltransferasa , Carcinoma Hepatocelular , Neoplasias Hepáticas , Anciano , Arilamina N-Acetiltransferasa/genética , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/genética , Estudios de Casos y Controles , Genotipo , Glutatión Transferasa/genética , Humanos , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/genética , Masculino , Polimorfismo GenéticoRESUMEN
Interindividual differences observed in the metabolism of xenobiotics have been attributed to the genetic polymorphism of genes, which code for enzymes involved in detoxification. This genetic variability seems to be associated with the individual's susceptibility to certain cancers, including nasopharyngeal carcinoma. In this study, we have investigated the genotypic frequencies of DNA polymorphisms of two detoxification's genes: the gluthatione-S-transferase (GST) and the N-acetyl transferase 2 (NAT2). The study has included 45 patients with nasopharyngeal carcinoma compared to 100 healthy Tunisian controls. The presence of the GSTM1 null and GSTT1 null polymorphism was screened by using a multiplex PCR procedure. A PCR-RFLP method was used to detect polymorphism for the most common alleles of the NAT2 gene. Allelic frequencies between the two groups were compared using a chi2 test and odds ratio with 95% confidence intervals were calculated. The results indicate that the genotypic frequency of GSTM10/0 between controls and patients was significantly different. This genotype confers an increased risk of nasopharyngeal carcinoma (Odds Ratio = 2.12, [0.64-4.7]). However, genotypic frequencies of NAT2*6/NAT2*6 were significantly higher in the group of nasopharyngeal carcinoma patients. The calculated Odds Ratio showed an association between this genotype and nasopharyngeal carcinoma. In conclusion, the increase of nasopharyngeal carcinoma risk in Tunisia seems to be associated with GSTM10/0 and NAT2*6/6 genotype.
Asunto(s)
Arilamina N-Acetiltransferasa/genética , Glutatión Transferasa/genética , Neoplasias Nasofaríngeas/enzimología , Proteínas de Neoplasias/genética , Polimorfismo Genético , Genotipo , Humanos , Neoplasias Nasofaríngeas/genética , TúnezRESUMEN
Our prospective study interested 41 patients, from 13 to 70 years old, and present a nasopharyngeal carcinoma confirmed histologically, during the period going from September 1999 to March 2000, and 45 healthy controls. A blood sample was collected from each patient before any treatment, as well as controls to measure serum LDH and its isoenzymes. Two groups of patients were selected after a period varying from 12 to 37 months with a mean of 29 months: 29 with favourable evolution, 12 with non favourable evolution. The mean serum total LDH and its isoenzymes values were significantly higher in patients than those in controls with values of variable p of 0.001 to 0.05. A significant correlation was found between ganglionnary extension and serum values of total LDH, LDH3 and LDH5. No significant difference were observed between the means serum total LDH before treatment and the clinical evolution of patients. Diagnostic contribution of total LDH is limited, by its ubiquitary character, but could constitute for LDH3 a good marker of the disease progression.